Troriluzole (BHV-4157) in Adult Participants With Obsessive Compulsive Disorder

Summary

The purpose of this study is to evaluate the efficacy of troriluzole as adjunctive therapy versus placebo in participants with obsessive compulsive disorder (OCD) who had an inadequate response to selective serotonin reuptake inhibitor (SSRI), clomipramine, venlafaxine, or desvenlafaxine treatment

Timeline

Start

2017-12-19

Primary completion

2020-06-02

Completion

2025-12-08

Outcome

Missed primary endpoint

registry analysis (superiority test); Troriluzole - Randomization Phase vs Placebo - Randomization Phase; p = 0.2202; LS Mean Difference -1.00 (95% CI -2.59 to 0.60); Mixed Models Analysis NCT03299166 ↗

Drugs

Indications